Quick Answer
AN2 Therapeutics, Inc. reported Operating Income of -$38.11 million for fiscal year 2025.
AN2 Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$38.11M | +32.9% |
| 2024 | -$56.79M | +18.4% |
| 2023 | -$69.64M | -64.8% |
| 2022 | -$42.26M | -95.9% |
| 2021 | -$21.57M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.04M | +28.4% | -39.1% |
| June 30, 2025 | -$7.22M | +54.6% | +37.5% |
| March 31, 2025 | -$11.54M | +36.9% | +17.7% |
| September 30, 2024 | -$14.01M | +22.9% | +11.8% |
| June 30, 2024 | -$15.88M | +4.3% | +13.2% |
| March 31, 2024 | -$18.30M | -14.1% | -0.6% |
| September 30, 2023 | -$18.18M | -54.5% | -9.5% |
| June 30, 2023 | -$16.60M | -60.7% | -3.5% |
- AN2 Therapeutics, Inc. showed an increase of +32.9% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, AN2 Therapeutics, Inc.’s operating income has declined by 76.6% (from -$21.57 million to -$38.11 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: